[Treatment of recurrent ventricular tachycardias using oral propafenone].

The effect of oral propafenone on prevention of pacing-induced ventricular tachycardia (VT) was studied in 11 patients. All patients experienced documented sustained VT refractory to 4.1 +/- 2 antiarrhythmic agents per patient including amiodarone in 8. Programmed electrical stimulation was performed before and 48-72 hours after oral propafenone (900 mg/day) 2-3 hours after the last dose. Two patients developed spontaneous incessant VT before the scheduled date of the study on propafenone, and were classified as aggravation. Propafenone prevented pacing-induced VT in 2 patients (successful results). In 3 additional patients the results were partial, as non-sustained VT was induced on propafenone whereas sustained VT could be provoked during the control study. In the remaining 4 patients, oral propafenone failed to prevent pacing-induced VT. Tachycardia cycle length increased in 3 (C = 284 +/- 129 P = 450 +/- 202 ms) and was shorter in 1 aggravation. The 5 patients with successful or partial results (45.4 p. cent), underwent long-term therapy with a mean follow up of 5.6 +/- 4 months. Recurrence of VT occurred in 2. The remaining 3 are well controlled. This study demonstrates that propafenone is able to prevent pacing-induced VT in a limited number of patients. Stimulation techniques are useful in order to detect patients with potential pro-arrhythmic effect.